Mild Traumatic Brain Injury Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Mild Traumatic Brain Injury Treatment Market is Segmented by Treatment (Drugs, Surgery), End Users, and Geography

Market Snapshot

mild traumatic brain injury treatment
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include increasing incidence of mild traumatic brain injuries, and ongoing product development and approval.

Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important, and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80–90 % of all TBI. Therefore the rising incidences and injuries being caused to the brain worldwide resulting in a high prevalence of target disorders are expected to impact the market in a positive manner.

Scope of the Report

As per the scope of the report, a patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function. It has been recognized that patients with a mild traumatic brain injury can exhibit persistent emotional, cognitive, behavioral, and physical symptoms, alone or in combination, which may produce a functional disability.

By Treatment
End Users
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hospital is Expected to Hold Significant Market Share in the End User Segment

The therapy for mild traumatic brain injury treatment usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility, or through outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed. 

Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding, or reduced oxygen supply to the brain.

emergency traumatic.png

North America Dominates the Market and Expected to do Same in the Forecast Period

Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.

Mild Traumatic Brain Injury Treatment Market - Growth  Rate by Region - Image

Competitive Landscape

The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB    , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence Of Mild Traumatic Brain Injuries

      2. 4.2.2 Ongoing Product Development And Approval

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework

      2. 4.3.2 Shortage Of Trained Professionals

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment

      1. 5.1.1 Drugs

      2. 5.1.2 Surgery

    2. 5.2 End Users

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinics

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Grace Laboratories LLC.

      2. 6.1.2 Integra LifeSciences Corporation

      3. 6.1.3 Medtronic PLC

      4. 6.1.4 Neuren Pharmaceuticals Ltd.

      5. 6.1.5 NeuroVive Pharmaceutical AB

      6. 6.1.6 Stemedica Cell Technologies Inc.

      7. 6.1.7 TEVA Pharmaceutical Industries Ltd.

      8. 6.1.8 Vasopharm GmbH

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Mild Traumatic Brain Injury Treatment Market market is studied from 2018 - 2026.

The Mild Traumatic Brain Injury Treatment Market is growing at a CAGR of 3.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

NeuroVive Pharmaceutical AB, TEVA Pharmaceutical Industries Ltd., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd. are the major companies operating in Mild Traumatic Brain Injury Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!